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ABSTRACT

Modulation of the Host Response to Tacaribe Arenavirus Infection in AG129 Mice
by MY-24

by

Eric Sefing, Master of Science
Utah State University, 2012

Major Professor: Brian B. Gowen
Department: Animal, Dairy and Veterinary Science

MY-24 is an aristeromycin derivative previously shown to protect AG129 type I
and II interferon receptor knockout mice from lethal challenge with Tacaribe virus
(TCRV). TCRV is nonpathogenic to humans, but is closely related to the highly
pathogenic New World arenaviruses that cause often-fatal viral hemorrhagic fever
syndromes. Remarkably, MY-24 prevented mortality without reducing TCRV burden in
the circulation or tissues. To investigate the mechanism by which MY-24 protects
AG129 mice against TCRV infection, we first characterized the natural history of disease
in the model with an emphasis on cytokine responses and vascular integrity to establish
the best times to evaluate the effects of MY-24 treatment on host responses believed to
contribute to pathogenesis and fatal outcome. We found that viral replication in the
blood and in various tissues precedes a hyperproduction of proinflammatory mediators
that may lead to the destabilization of the endothelial barrier and increased vascular
leakage believed to contribute to terminal shock associated with severe cases of
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hemorrhagic fever. We also found slightly reduced virus titers in certain tissues from
MY-24-treated mice, suggesting that there may be a weak antiviral effect; however,
TCRV was not cleared from lung, spleen, brain or kidney in recovering animals out to 40
days post-infection, indicative of the establishment of chronic infection in mice that are
able to survive the initial challenge. Neutralizing antibodies do not appear to play a
major role in the antiviral effect of MY-24, whereas reductions in several key
proinflammatory cytokines in mice treated with MY-24 may serve to reduce vascular
leakage caused by TCRV infection.
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PUBLIC ABSTRACT

Modulation of the Host Response to Tacaribe Arenavirus Infection in AG129 Mice
by MY-24

by

Eric Sefing, Master of Science
Utah State University, 2012

Major Professor: Brian B. Gowen
Department: Animal, Dairy and Veterinary Science

MY-24 is a new antiviral compound recently shown to protect
immunocompromised mice from lethal challenge with Tacaribe virus (TCRV). Tacaribe
virus is incapable of causing disease to humans, but is closely related to the highly
pathogenic New World arenaviruses that cause often-fatal viral hemorrhagic fever
syndromes. Remarkably, MY-24 prevents mortality without reducing virus burden in the
circulation or tissues. To investigate the mechanism by which MY-24 protects AG129
mice against Tacaribe virus infection, we first characterized the natural history of disease
in the model with an emphasis on host immune response and blood vessel function to
establish the best times to evaluate the effects of MY-24 treatment on host immune
responses believed to contribute to disease severity and fatal outcome. We found that
viral replication in the blood and in various tissues precedes an overzealous immune
response that may lead to the destabilization of the blood vessels and increased fluid
leakage believed to contribute to fatal shock associated with severe cases of hemorrhagic
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fever. We also found slightly reduced virus titers in certain tissues from MY-24-treated
mice, suggesting that there may be a weak antiviral effect; however, TCRV was not
cleared from lung, spleen, brain or kidney in recovering animals out to 40 days postinfection, indicating the establishment of a chronic infection infection in mice that are
able to survive the initial challenge. Neutralizing antibodies do not appear to play a
major role in the antiviral effect of MY-24, whereas reductions in several key factors that
cause inflammation in mice treated with MY-24 may serve to reduce fluid leakage caused
by Tacaribe virus infection.
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CHAPTER 1
INTRODUCTION

1. Arenaviruses - Emerging human pathogens
A group of close to 30 arenaviruses make up the Arenaviridae family of viruses
[1]. They are a diverse group of enveloped, single-stranded negative sense RNA viruses
with bi-segmented genomes, serologically and phylogenetically divided into Old World
and New World lineages [2,3]. Novel arenaviruses are being discovered, on average,
every 2-3 years, and the recent emergence of new pathogenic arenavirus species is of
great concern as these viruses are zoonotic agents harbored in rodent reservoirs with the
potential to come in close contact with expanding rural human populations [4,5].
Arenaviruses develop asymptomatic chronic infections in their rodent hosts and can be
transmitted to humans by inhalation of aerosolized excreta or contaminated secretions.
Transmission from persistently infected rodents to humans can also occur through contact
of infectious materials with skin abrasions. Humans infected with arenaviruses develop a
wide range of disease signs and symptoms from asymptomatic or mild febrile illnesses
that clear within a few days to severe hemorrhagic fever (HF) requiring prompt medical
attention. The onset of arenaviral HF proceeds inconspicuously leading to
immunosuppression, high viremia, hypercytokinemia, increased vascular permeability,
extensive organ damage and eventually hypovolemic shock [6]. There are presently 7
arenaviruses known to cause viral HF. The group includes 5 New World viruses (Junin,
Machupo, Guanarito, Sabia, and Chapare) present in areas of South America, and two
Old World viruses (Lassa and Lujo) found in defined regions of Western and South
Africa [7,8].
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The New World arenaviruses (NWA) are comprised of 3 distinct clades, designated
clade A, B and C, collectively within the Tacaribe complex [2]. Clade B contains the 5
highly pathogenic arenavirues and several closely related non-pathogenic viruses
including Tacaribe virus (TCRV), first isolated in 1956 from a fruit-eating bat (Artibeus
lituratus) on the island of Trinidad [9]. TCRV is most closely related to Junin virus
(JUNV) [7], the etiologic agent of Argentine HF. JUNV has produced the greatest
disease burden due to infection by the pathogenic NWA, with case fatality rates ranging
from 15-30% in hospitalized patients [10]. Dysregulation of the host innate immune
response by JUNV and other pathogenic NWA is believed to impair the development of
protective immunity, leading to morbidity and potentially lethal results [6,11]. Those that
survive infection develop an antiviral immune response that controls infection with the
eventual systemic clearance of the virus.
In addition to being public health concerns from natural transmission in endemic
regions of South America, the pathogenic NWA are considered bioterror agents that
could be intentionally released in highly populated areas across the globe [12]. While
arenaviruses are a concern to the health and safety to the human population in close
contact with the natural rodent reservoirs harboring the highly pathogenic clade B
arenaviruses, the aerosol transmissibility of these viruses makes them serious biothreats.
Further, the lack of safe and effective therapeutic options also contributes to the
designation of JUNV and other HF-causing NWA as highest priority category A NIAID
pathogens [12]. The only proven effective vaccine against an arenavirus HF is the JUNV
Candid #1 attenuated virus vaccine [13]. However, the vaccine is only indicated for
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those at high risk in the endemic regions of Argentina, such as agricultural workers and
those that live near areas prone to infestation by the rodent host, Calomys musculinus
[14]. Currently, Immune plasma is considered the standard of treatment for Argentine
HF; however, the lack of efficacy in clinical disease past 8 days of evolution, the risk of
transfusion associated diseases, and difficulties of maintaining sufficient stockpiles of
immune plasma support continued drug development efforts [10].
The Old World arenaviruses [15] include the prototypical arenavirus, lymphocytic
choriomeningitis virus (LCMV), a medically important arenavirus particularly in immune
compromised individuals, and Lassa virus (LASV), by far the arenaviral HF agent that
has caused the greatest morbidity and mortality. LCMV infections generally cause mild
febrile illness sometimes associated with aseptic meningitis, but can also cause severe
disease in fetuses or newborns [16]. Organ transplant patients are also at higher risk of
productive infection and have high mortality during outbreaks of LCMV [17]. Lassa
Fever, the most significant arenaviral disease in terms of number of cases, was first
described during a 1969 outbreak in Nigeria [18]. LASV is endemic to Western Africa
and afflicts approximately 300,000 people with an estimated 5000 deaths annually [19].
In endemic regions of Western Africa, LASV infection causing severe disease results in
mortality rates of >15%, with up to 50% case fatality in hospital acquired infections
[20,21]. More recently, Lujo virus emerged in Southern Africa with the index case and 3
of the 4 caregivers exposed to the virus succumbing to the infection (80% lethality) [5].
The only survivor was treated with ribavirin, but it is not clear whether the intervention
had a significant effect on the outcome of that fifth case. In patients with severe Lassa
fever, ribavirin has been shown to have some efficacy in treating disease within the first
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six days of evolution [22]; however, previously noted side effects that include hemolytic
anemia are less than desirable when treating a disease where hemorrhaging can be
significant [23]. Nevertheless, ribavirin is considered the standard of care in Western
Africa for treating severe LASV infections [24], and in the US in the event of a
bioterrorist act, an imported case, or laboratory accident [12].

2. Arenavirus molecular and cell biology
Genetic diversity is considerable among the Arenaviridae family members, even
within the same virus species. Despite the genetic variability at the nucleotide and amino
acid levels, there are common features shared by all arenaviruses. Arenavirus virions are
generally pleomorphic particles ranging from 50-300 nm in diameter and contain electron
dense ribosomal particles, which under an electron microscope give the virus a grainy
appearance [25]. Consequently, the family name “arena” is derived from the Latin term
“arenosus” which means “sandy” [25]. The arenaviruses are non-lytic and replicate
strictly in the cytoplasm. The genome consists of two single stranded ambisense RNA
segments encoding 4 proteins [26]. The large (L) and small (S) viral RNA segments each
include two open reading frames in mutually opposite orientations separated by a
noncoding intergenic region with a predicted stable hairpin structure [26]. The S segment
is 3.4 kb in length and encodes the viral nucleoprotein and glycoprotein precursor (GPC)
which is post translationally cleaved to form GP1 and GP2 [27]. The L segment is 7.2 kb
in length and encodes the viral RNA-dependent RNA polymerase (L protein) and a
matrix (Z) protein [28]. In addition to its polymerase function, L also has 5’
endonuclease activity for “cap-snatching”. The GPC and Z matrix proteins are translated
from subgenomic virus sense mRNA, while the nucleoproteins and RNA polymerase are
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translated from subgenomic virus anti-sense mRNA. NP, Z and L are translated in the
cytosol while the viral GPC is a type I membrane protein synthesized in the host cell’s
secretory pathway [29].
NP is the major structural protein encapsidating the viral genome and also has capbinding activity to assist L-mediated viral replication and transcription [30]. The NP
associates with viral RNA to form nucleocapsids [15]. The L protein is also incorporated
into the viral nucleocapsid [31,32]. The GPC protein is initially synthesized as a single
polypeptide cleaved during processing in the endoplasmic reticulum into two
glycoproteins, the N-terminal GP1 domain and a transmembrane GP2, by a host cell
protease [27,33]. GP1/GP2 forms a tripartite complex with a stable signal peptide (SSP),
which represents the arenavirus functional unit for host cell attachment and entry [34].
The GPC is dependent upon the SSP for proper maturation, transport, and membrane
fusion [1].
The ability of clade B arenaviruses to cause disease has been directly linked to GP1
binding to transferrin receptor 1 (TfR1) [35], the principal receptor mediating attachment
and entry of the NWA that cause HF [36]. Within clade B, only the pathogenic
arenaviruses utilize human TfR1, whereas nonpathogenic relatives such as TCRV and
Amapari virus recognize the TfR1 ortholog in their respective rodent hosts [37]. The
major receptor for clade C and OWA has been found to be α-dystroglycan [38,39]. The
receptor for the clade A arenaviruses has not been elucidated.
Once the binding of pathogenic NWA to TfR1 is initiated, the virion is endocytosed
and GPC-mediated fusion of the viral and endosomal membranes is activated in response
to a change to low pH of the maturing endosome [1]. Clade A and B NWA enter the cell

6
through clathrin-mediated endocytosis while OWA (LASV and LCMV) entry is
independent of clathrin [40]. Once penetration into the cytoplasm occurs the viral
ribonucleoprotein acts as a template for transcription and replication mediated by the
viral polymerase [41]. Viral transcription and replication is dependent on the L and NP
proteins while delayed expression of the Z protein demonstrates a dose dependent
inhibitory effect on these processes [31,42,43]. The Z matrix protein is essential to
arenavirus budding while the physical interaction of GP and Z is required for the
incorporation of GPs into arenavirus virion particles [44]. The formation of the virion
particles and the budding of these infectious progeny from infected host cells requires the
assembled RNP to associate at the host cell surface enriched with viral GP. The
endosomal sorting complex required for transport of RNP components are recruited by
the GP and Z interaction to facilitate virion assembly and release from the infected host
cell [45] In addition to its critical role in virion egress, the Z protein has been shown to
interfere with the type I IFN response [46].

3. Animal models of arenaviral
hemorrhagic fever
Proof-of-concept studies utilizing animal models that recapitulate the features of
human disease are essential to advance development of promising therapeutic agents
towards practical clinical applications. For HF arenaviruses, the greatest challenge has
been the lack of disease models in immune competent mice. The currently available
infection models are shown in Table 1.
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Table 1. Animal Models for the Study of Arenaviral HF
Virus

Disease

Animal model

Selected references

Lassa

Lassa fever

Rhesus macaque

[47], [48], [49]

Cynomolgus macaque

[50], [51], [52]

Marmoset

[53]

Guinea pig

[54], [55]

HHDa mouse

[56]

MHC-I-/-b mouse

[56]

Lassa virus replication

Lujo

Hemorrhagic fever

Guinea pig

[57]

LCM

Hemorrhagic fever

Rhesus macaque

[58]

Guinea pig

[59]

Guinea pigc

[60], [61], [62]

Hamster

[63], [64], [65]

Hamster

[66], [67]

Rhesus macaque

[68], [69]

Marmoset

[70], [71]

Guinea pig

[72], [73], [74]

AG129d mouse

[75]

AG129d mouse

[76]

Rhesus macaque

[77], [78], [79]

Cynomolgus macaque

[78]

African green monkey

[80], [81]

Guinea pig

[82]

STAT-1-/-e mouse

[83]

Pichinde

Hemorrhagic fever

Pirital
Junin

Argentine hemorrhagic fever

Tacaribe
Machupo

Bolivian hemorrhagic fever

8
Guanarito

Venezuelan hemorrhagic fever

Guinea pig

[84]

Flexal

Hemorrhagic fever

Hamster

[85]

a

Genetically engineered mouse that expresses a human/mouse-chimeric HLA-A2.1 molecule in place of

the murine MHC-I.
b

β2-microglobulin-deficient mouse (MHC-I-/-).

c

Virus adapted to produce lethal disease.

d

Type I and II interferon receptor-deficient mouse.

e

Signal transducer and activator of transcription 1-deficient mouse (STAT-1-/-).

Lymphocytic choriomeningitis, LCM.

Work with most of the arenavirus HF models (Lassa, Lujo, Junin, Machupo, and
Guanarito) is restricted to approximately 6 biosafety level (BSL-4) maximum
containment laboratories in the US, and several facilities abroad. Accessibility to such
labs and the high cost associated with conducting studies in BSL-4 has limited research in
this area. Although more accessible and less biohazardous, the use of Pichinde (BSL-2),
Pirital (BSL-2), and Flexal (BSL-3) clade A arenavirus models is less than ideal
considering that all the HF NWA are in clade B. To this end, we developed a model
based on the challenge of AG129 mice with the clade B TCRV, a virus that can be
worked with safely in BSL-2 containment [76].
In addition to its relatedness to JUNV, TCRV can be adapted to produce dramatic
cytopathic effect (CPE) making it amenable to use in high-throughput screening (HTS)
in vitro for identification of small molecule inhibitors that could be useful against the
pathogenic clade B relatives. Compounds identified by this approach that demonstrated
antiviral activity and specificity against TCRV were also found to be active against
JUNV and other pathogenic clade B NWA in other cell culture-based assays [86]. The
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lead compound, ST-294, was further evaluated in a previously described newborn
BALB/c mouse model [87]. Effective treatment following TCRV challenge of 4-day-old
BALB/c mice by the intraperitoneal (i.p.) route provided proof-of-concept that ST-294
had activity in vivo [86]; however, the difficulty of working with newborn animals
prompted others to pursue other alternatives. This lead to the development of the AG129
IFN-α/β and γ receptor-deficient mouse TCRV challenge model [76]. This model has
been particularly useful in evaluating promising anti-arenavirus compounds that have
little to no activity against the clade A Pichinde virus (PICV) in vitro. Until the
development of the TCRV model, only animal studies in hamsters challenged with PICV
could be performed in BSL-2, requiring both activity against PICV and far greater
quantities of compound, which are often limited in early stages of drug discovery and
development. In addition, work with the apathogenic TCRV greatly reduces the risks
associated with arenavirus research. The inability of TCRV to antagonize the host
interferon response like other NWA likely contributes to its lack of pathogenicity [88].

4. Small molecule experimental therapies
for treatment of arenaviral infections
While there is an expanding list of compounds that have demonstrated antiarenaviral activity in vitro, most have not been evaluated in experimental animal models
[8], and, thus, are beyond the scope of this literature review. There are, however, several
promising small molecules that have shown efficacy in several of the models described in
section 3. ST-294 is potent and selective compound that was effective in the newborn
TCRV mouse challenge model; however, activity was restricted to clade B NWA [86]. A
second compound with expanded spectrum, ST-193, was found to be protective against
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the LASV infection in strain 13 guinea pigs [89]. The ST compounds represent a new
class of viral entry inhibitors that disrupt the interaction between the GP2 subunit and the
SSP [90,91]. With its broad-spectrum activity against both Old and NWA, ST-193 is the
most promising lead for further development. Because it has a mechanism of action
distinct from ribavirin [1,92], combination therapy studies testing ST-193 and ribavirin in
guinea pig or nonhuman primate models of arenaviral HF should be considered.
Favipiravir (T-705) is a compound originally described as a potent influenza virus
inhibitor [93,94], and has advanced through clinical trials in Japan for the treatment of
influenza virus infections. The compound is presently in phase II clinical trials in the US
for the same indication. In addition to its activity against influenza, several laboratories
have shown that the compound broadly inhibits RNA virus infections [95]. If approved
for use against influenza virus, favipiravir could be used “off-label” for other viral
diseases including arenaviral HF, as the compound has been shown to inhibit multiple
arenaviruses including JUNV [96]. Favipiravir acts like a purine nucleoside analog
inhibiting the influenza virus RNA dependent RNA polymerase, and the polymerase is
also the likely arenavirus target [96,97]. Remarkably, favipiravir has been shown to be
active against advanced PICV infection even when delaying treatment until after the
onset of clinical disease [98,99]. Encouraging results have fueled further development of
favipiravir as a therapeutic for the treatment of JUNV infection in guinea pigs, and
ultimately nonhuman primates.
As a result of in vitro screening efforts, our lab identified MY-24, an aristeromycin
derivative, as an inhibitor of TCRV in a series of cell culture screening assays. Because
the compound was also found to be active against the attenuated Candid #1 vaccine strain
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of JUNV, it was evaluated in the TCRV AG129 mouse infection model [76]. In those
experiments, MY-24 consistently protected close to 100% of treated mice from lethal
challenge with TCRV. Most impressive was the fact that therapy was still effective even
when delaying the initiation of MY-24 treatment as late as 5 days post infection [76].
Remarkably, however, treatment did not significantly reduce virus titers, suggesting that
the beneficial protective effect may be due to amelioration of the pathogenesis related to
an overzealous host response. The current thinking is that excessive production of
inflammatory mediators triggers vascular leak, and ultimately hypovolemic shock is the
cause of death in severe cases of viral HF [100,101].
At present, it is unclear how MY-24 is protecting TCRV-challenged mice from
mortality. The compound is an analog (5'-homoaristeromycin) of aristeromycin, a
carboxylic nucleoside antibiotic that has been shown to inhibit AMP synthesis in
mammalian cells and most importantly, in the context of antiviral research, has
demonstrated inhibition of the enzyme S-adenosylhomocysteine hydrolase (AdoHcyase)
[102,103]. AdoHcyase catalyzes the hydrolysis of S-adenosylhomocysteine to form
adenosine and homocysteine products that are crucial in the methylation process
associated with various biological processes, including RNA capping [104]. Because of
toxicity from 5'-phosphate formation, aristeromycin has not advanced in development as
an antiviral agent [105,106]. In contrast, MY-24 is far less toxic than aristeromycin, and
was well tolerated in mice. Despite having anti-TCRV activity in cell culture, the
compound does not appear to act in a similar fashion in mice, as reduced titers were not
evident. Thus, we hypothesize that the MY-24 is reducing hypercytokinemia elicited in
response to TCRV infection, and thereby limiting vascular leak and its putative

12
contribution to the demise of the AG129 mice.
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CHAPTER 2
MATERIALS AND METHODS

1. Animals
Six- to seven-week-old AG129 IFN-α/β and -γ receptor-deficient mice were used
in these experiments and were obtained from the breeding colony at USU. They were
fed irradiated mouse chow and autoclaved water ad libitum.

2. Ethics statement
All animal procedures complied with USDA guidelines and were conducted at the
AAALAC-accredited Laboratory Animal Research Center at Utah State University
(USU) under protocol 1425 approved by the USU Institutional Animal Care and Use
Committee.

3. Virus
TCRV, strain TRVL 11573, was obtained from American Type Culture Collection
(ATCC; Manassas, VA). The virus stock (106.35 50% cell culture infectious doses
(CCID50)/ml) was prepared from clarified liver homogenates from AG129 mice
challenged with TCRV (2 passages in Vero 76 African green monkey kidney cells).
Virus stock was diluted in sterile MEM plus 50 µg/ml gentamicin and inoculated by
bilateral i.p. injections totaling 0.2 ml.

4. Natural history of disease in AG129
mice challenged with TCRV
Mice were sorted based on age and gender into 9 groups of 4 animals per group,
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and 1 group with 5 mice to account for projected deaths late in the course of infection.
The animals were ear tagged and individual weights were determined every other day
starting on day 0 relative to the time of virus infection with approximately 450 CCID50
of TCRV. Groups of 4 TCRV-infected animals were sacrificed daily, with 1 of the 5
mice in the day-10 group succumbing prior to sacrifice. Ten sham-infected mice
(normal controls) were included in the study for daily sacrifice [one per day] and
comparison to the TCRV-challenged animals. Serum and liver, spleen, brain, kidney,
and lung tissues were obtained for virus titer determination and cytokine profiling. The
spleens from all animals were weighed prior to processing for virus titers. Whole blood
collected in EDTA-coated tubes was analyzed for hematology using the VetScan HMT
(Abaxis Inc. Union City, CA). A sample of each tissue was preserved in 10% formalin
and sent to the Ross A. Smart Veterinary Diagnostic Laboratory (VDL; Logan, UT) for
histopathology. Here and elsewhere, clarified tissue homogenates in minimal essential
medium and serum were stored at -80 °C until time of analysis.

5. Tissue virus titer determinations
Virus titers were assayed using an infectious cell culture assay as previously
described [96]. Briefly, a specific volume of tissue homogenate or serum was serially
diluted and added to triplicate wells of Vero 76 (African green monkey kidney) cell
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monolayers in 96-well microtiter plates. The viral cytopathic effect (CPE) was
determined 7-8 days post-virus inoculation, and the titers were calculated by endpoint
titration [96]. The assay detection ranges were 2.8 - 9.5 log10 CCID50/g of tissue or 1.8 8.5 log10 CCID50/ml of serum. In samples presenting with undetectable tissue or serum
virus, a value of < 2.8 or 1.8 log10 was assigned, respectively. Therefore, the mean virus
titer for samples with undetectable levels of virus is likely an overestimate of the actual
viral load. For statistical analysis, values of 1.8 or 2.8 log10 were assigned for samples
with undetectable virus levels.

6. Assessment of vascular leakage
Vascular permeability was determined by intravenous administration of Evans blue
dye (EBD) (Sigma-Aldrich, St. Louis, MO) and tracking its diffusion into various tissues
as previously described . At designated times following infection, untreated or treated
mice were anesthetized with isoflurane and injected retro-orbitally with a 0.5% EBD
phosphate-buffered saline (PBS) solution. Retro-orbital injections were given using a 27guage needle by carefully inserting the tip approximately 1 mm from the outermost edge
of the eye into the membrane exposed by gently pulling the skin away from the eye.
Once the membrane has been penetrated, the EBD is slowly injected into the eye for
absorption by the capillary nexus at that site. After a 3 h period, blood was collected by
cheek bleed, and the animals were extensively transcardially perfused with PBS. Similar
sized sections of liver, spleen, lung, and kidney tissues were harvested, placed in preweighed 1.5 ml microtubes for weight determination, and 0.5 ml of formamide was added
for complete immersion of all samples. The EBD was extracted from tissue samples by
overnight incubation at 37 degrees C. A 0.2 ml volume from each tube was placed into a
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96-well microtiter plate and the absorbance at 610 nm was measured. Relative EBD
content in the serum was determined from 1:10 diluted samples measured at 610 nm and
740 nm. The absorbance at 740 nm was subtracted from the 610 nm absorbance values
to remove contributions due to hemoglobin contamination. Data are expressed as a ratio
of absorbance/g of tissue:absorbance of a 10-fold dilution of serum sample.

7. Compounds.
MY-24 was provided by Stewart Schneller (Auburn University, Auburn, AL). The
synthesis of the compound has previously been reported [107] and its in vitro and in vivo
activity against TCRV has been described [76]. MY-24 was dissolved in sterile saline
solution and administered by i.p. injection.

8. MY-24 mechanism of action studies
Mice were sorted based on age for males and weight for females into 6 TCRV
infected groups of 5-6 animals per group. The animals were ear tagged and individual
weights were determined every third day. Animals were treated with saline vehicle
placebo or 25 mg/kg of MY-24, once daily for up to 8 days starting 3 days post-challenge
with ~450 CCID50 of TCRV. Groups of 5 MY-24- and placebo-treated mice were
sacrificed on day 8, and remaining 4-5 mice per group on days 16, 24, 32 and 40 relative
to time of infection. Placebo-treated animals were not included for these later time points
because they would not be expected to survive the TCRV challenge. Five sham-infected
normal control mice were included in the study for sacrifice at the different time points
and comparison to the TCRV-challenged animals. Serum and liver, spleen, brain, kidney,
and lung tissues were collected for analysis, as described above. Due to death prior to
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time of sacrifice, 1 of 5 animals in the 24- and 32-day groups, and 2 of 6 animals in the
40-day group were not included in the analysis. Day-8 samples were assayed for
neutralizing antibody titers and profiled for systemic cytokine expression. Spleen
samples collected on day 8 were also included in the cytokine analysis.

9. Cytokine multiplex profiling
Tissue and serum concentrations of 16 cytokines (IL-1α, IL-1β, IL-2, IL-3, IL-4,
IL-5, IL-6, IL-9, IL-10, IL-12, MCP-1, IFN-γ, TNF-α, MIP-1α, GM-CSF, and RANTES)
were evaluated in TCRV-infected mice using Q-Plex mouse cytokine arrays (BioLegend,
San Diego, CA) as recommended by the manufacturer. Samples from normal control
animals were included to establish baseline cytokine concentrations in AG129 mice. For
the natural history study, fold change was calculated relative to the normal control values
(n=3-6) for the respective cytokines. For the experiment to determine the effects of MY24 treatment on cytokine induction in infected mice, data are presented as pg/ml of serum
or pg/g of spleen tissue.

10. Serum plaque reduction and
neutralization (PRNT) titers
Neutralizing antibody titers were determined by standard PRNT assay. Briefly, 6well cell culture plates were seeded with Vero 76 cells to achieve ~70-80 % confluence.
Equal volumes of media containing ~400 CCID50 of TCRV was added to serial 2-fold
dilutions of heat-inactivated (56°C for 30 min) serum samples diluted in MEM
supplemented with 2% FBS. Experimental samples were diluted 1:5 to 1:160. The
immune serum control was diluted starting at 1:250. The serum plus TCRV mixture was
incubated at 37°C for 2 h. After removing media from cells, 200 µl of the serum-TCRV
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mixtures were added to respective wells of 6-well plates and incubated at 37°C for 2 h,
while rocking plates every 10 min to prevent drying of cells and to distribute virus
evenly. After the 2-h absorption period, each well was washed twice with 1 ml of DPBS
prior to the addition of a warmed solution of 2 ml of 2% sea plaque agarose (Lonza,
Rockland, ME) and an equivalent amount of 2X MEM/4% FBS/gentamicin. Plates were
incubated 5 min at 4°C to solidify agarose, and then incubated at 37°C for 6 days, at
which time 1 ml filtered-sterilized 0.034% neutral red solution was added to each well
and incubated an additional 2 h. Neutral red was aspirated and plaques enumerated with
the aid of a light box. Plates were further incubated overnight at 37°C and read on day 7
to verify accuracy of initial plaque count. The neutralizing antibody titers were expressed
as the highest dilution of serum reducing the average number of plaques present in the
virus control wells (TCRV incubated with normal serum) by 50% or greater (PRNT50).

11. Statistical analysis
For analyzing differences in viral titers, cytokine levels, plaque reduction
neutralization titer and vascular permeability, one-way analysis of variance [108] with
Newman-Keuls posttests were performed. The Mann-Whitney test (two-tailed) was used
for evaluating differences in spleen weights and hematology. All statistical evaluations
were done using Prism (GraphPad Software, CA).
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CHAPTER 3
RESULTS
1. Natural history of TCRV-infection
in AG129 mice
One of the goals of the present study was to determine the kinetics of viral
replication of TCRV in AG129 mice, as part of a more comprehensive characterization of
the infection model. As seen in Figure 1, all tissues examined harbored virus. Virus first
became apparent systemically on day 6 in 2 of 4 challenged mice, and titers gradually
increased until reaching mean levels above 7.25 log10 CCID50/ml on day 9 (Figure 1A).
Liver virus was barely detectable in a single animal on day 6, rising to 7.75 log10
CCID50/g by day 9 (Figure 1B). By gross visual examination, liver samples taken from
day 10 mice were a pale light color in 2 of the 4 survivors. Substantial lung virus titers
could be detected in 75% of the mice on day 7, with increasing burden thereafter,
reaching peak levels (~6.75 log10 CCID50/g) on day 10 (Figure 1C). Gross visual
examination of lungs revealed necrotic lesions on day 9 and thereafter. The first organ to
present with significant amounts of TCRV replication was the spleen, with >4.75 log10
CCID50/g on day 5 of the infection, and sustained virus burden of >6.5 log10 CCID50/g
out to day 10 (Figure 1D). In several spleen samples collected on and after day 8, gross
examination revealed pyogranulomatous lesions and a pale light coloration, in addition to
splenomegaly. TCRV was found in the brain in 1 of 4 animals on day 8 and all infected
animals thereafter, with up to 6 log10 CCID50/g present on days 9 and 10 (Figure 1E).
Substantial kidney virus was not observed until day 8 of infection, with the highest mean
viral loads of >6.5 log10 CCID50/g seen on days 9 and 10 (Figure 1F).
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Figure 1. Temporal Analysis of Serum and Tissue Virus Titers in AG129 Mice
Challenged with TCRV. Groups of 4 animals were sacrificed on the specified days of
infection for analysis of A) serum, B) liver, C) lung, D) spleen, E) brain, and F) kidney
virus titers. One of 5 mice in the day-10 group succumbed prior to the time of sacrifice.

21
The mean weight of the TCRV-infected mice dropped sharply after day 6 (Figure
2). Splenomegaly was also observed as early as day 6 in infected mice, with spleens
doubling in weight compared to the sham controls (Figure 3). WBCs increased
precipitously starting on day 8, as did the lymphocyte and granulocyte populations (Table
2). Monocytes were slightly increased, also starting on day 8. Notably, platelet counts
did not decrease in the TCRV-infected animals (Table 2), which is a characteristic feature
of South American hemorrhagic fever [101]. No other significant changes were seen in
the hematologic analysis.
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Figure 2. Weight Change in AG129 Mice during the Course of TCRV-Infection.
The data are represented as the group mean and standard deviation of the percent change
in weight of surviving animals relative to their starting weights, measured at 3-day
intervals. n=40, 36, 28, 20, 12, and 4 for the TCRV-infected mice, and n=10, 9, 7, 5, 3,
and 1 mouse for the normal controls, on day 0, 2, 4, 6, 8, and 10, respectively.
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Figure 3. Spleen Weights from Infected AG129 Mice during TCRV-Infection. The
data represent the mean and standard deviation from groups of 4 TCRV-infected mice
sacrificed at the indicated times. Data from 1 normal control animal per day are included
for comparison. *P < 0.05 compared to day 1 TCRV infected animals.
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Table 2a. Hematology Analysis in TCRV-Infected AG129 Mice from Days 1 to 10 Post-Infection.
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Cytokine levels were examined on days 5-10 in serum, brain and lungs, days 4-10
for kidney, days 3-10 for spleen, and days 2-10 for liver. As shown in top left panel of
Figure 4, serum concentrations of IL-6, IL-10, IFN-γ, and MIP-1α in were increased >50fold as TCRV progressed. Levels of TNF-α and MCP-1 also increased over time, and, in
addition to IL-6, have been associated with severe disease in cases of viral hemorrhagic
fever [101]. Overall, the cytokines included in the analysis were broadly induced in
spleens from infected mice (Figure 4, lower left panel). Notably, however, IL-6, MCP-1,
IFN-γ, and MIP-1α, actually demonstrated a trend of induction over time, whereas the
concentrations of most other cytokines fluctuated relative to the levels observed in
uninfected mice.
Cytokine expression in the livers from infected animals were less remarkable than
the high levels observed in the sera and spleen, with temporal induction observed with
MCP-1 and MIP-1α, and consistently high levels of IFN-γ (Figure 4, top center panel).
In lung tissues, increased production in numerous cytokines was observed later in the
course of infection (days 9 and 10) (Figure 4, top right panel). A temporal pattern of
increasing concentrations of IL-6, IL-10, MCP-1, IFN-γ, MIP-1α, and RANTES was
evident. In general, cytokine production in kidney and brain tended to be suppressed by
TCRV infection (Figure 4, bottom right panels).
Although there was histopathology present in spleens by day 7 (Appendix, Table
A1), evidence of disease was not seen in other tissues until day 8 of infection. Typical
liver lesions included moderate numbers of portal lymphocytes and histiocytes (Figure
5A) and scattered degenerate/necrotic hepatocytes surrounded by small numbers of
neutrophils or lymphocytes.
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Figure 4 . Cytokine and Chemokine Response to TCRV-Infection. Groups of 4
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infection and the serum and tissue concentrations of selected cytokines were determined
using a multiplexed array including the indicated cytokines. Fold change in expression is
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Spleens of infected mice had hyperplastic follicles, follicular lympholysis and increased
numbers of interstitial neutrophils (Figur
(Figure 5B). Findings from day-9
9 and 10 livers and
spleens had similar pathology to that descri
described for day-8
8 tissue samples (Appendix,
Table A1).
). There was no kidney or brain histopathology
pathology associated with advanced
TCRV infection in the AG129 mice
mice. Lung histopathology
topathology was mild to non-existent
non
on
day 8, with the most profound histopathology observe
observed
d on day 9 (Appendix, Table A1).

Figure 5. Histologic Examination
xamination of Liver and Spleen Sections
ections from TCRV-Infected
TCRV
AG129 Mice. Representative A) liver and B) spleen histopathology on day 8 of TCRV
infection in AG129 mice. C) Liver and D) spleen tissue from healthy sham-infected
sham
mice. Tissue sections were stained with hematoxylin and eosin.
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If we are to consider therapeutic strategies aimed at maintaining vascular integrity
in order to limit capillary leakage that ultimately results in plasma volume loss, multiorgan failure and shock, we must first establish that vascular hyperpermeability results
from TCRV infection in the AG129 mouse infection model. Thus, we also performed a
separate time course analysis of vascular permeability during TCRV infection in AG129
mice by tracking the movement of retro-orbitally injected EBD into various primary
tissues. In this study, TCRV-challenged mice exhibited clear signs of clinical illness
including lethargy and ruffling of fur by day 8 and 9, and the deteriorating condition of
the animals was reflected in loss of body weight (Figure 6). By day 10, the infected mice
were approaching a moribund state and the animals that were the most morbid did not
show markedly blue extremities as seen in the normal controls or less ill mice (not
shown). This is consistent with previously observed lack of perfusion in a model of acute
arenavirus infection in hamsters, likely due to hypotension associated with vascular leak
[65].
When measuring systemic EBD levels, serum concentrations were reduced in the
TCRV-infected control animals on day 8, 9 and 10, suggesting leakage of the dye into the
viscera (Figure 7A). However, we cannot rule out the possibility that the lower systemic
EBD levels seen at advanced stages of illness in the TCRV-infected mice may be due to
lack of absorption from the orbital capillary nexus. Therefore, to more accurately access
vascular leak of EBD, the tissue concentrations were normalized to amount of dye
present in the serum. Liver, kidney, lung and spleen showed a markedly higher average
of tissue to serum ratio in the TCRV-infected animals compared to the sham-infected
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mice on day 8, 9 and 10 (Figure 7B-E), indicating that vascular leakage is occurring and
may be an important factor in the demise of the AG129 mice challenged with TCRV.
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Figure 6. Individual Animal Body Weight Change During the Course of the
Vascular Permeability Study. TCRV- and sham-infected mice in the vascular leakage
study were weighed on day 0, 2, 4, 6, 8, 9, and 10 post-infection. The data are presented
as the group mean and standard deviation of the percent change in weight of surviving
animals relative to their starting weights.
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Figure 7. Evaluation of Vascular Permeability During TCRV-Infection in AG129
Mice. TCRV- and sham-infected mice were infused with EB dye on day 4, 7, 8, 9 and 10
of infection and systemic levels, as well as leakage into the viscera was evaluated. A)
Serum EB dye levels and ratios of tissue to respective serum levels are shown for B)
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separate experiments. *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 compared
to sham-infected animals.
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2. Characterization of the protective effect
of MY-24 during TCRV- infection in
AG129 mice
The second aim of this study was to measure the ability of MY-24 to clear TCRV
from the circulation and tissues in surviving animals successfully treated with the
compound. Groups of TCRV-challenged mice treated with 25 mg/kg/day MY-24 were
sacrificed on days 8, 16, 24, 32 and 40. Placebo-treated mice were included for the day-8
comparison. On day 8 of the infection, 3 of the 5 MY-24- and placebo-treated mice had
detectable virus loads in the serum (Figure 8A). All mice were viremic on day 16, but
TCRV was no longer detectable by 24 days in the MY-24-treated mice. As seen with the
serum, virus titers in the liver were slightly higher in the placebo-treated animals on day 8
(Figure 8B). Peak viral loads of ~7.5 log10 CCID50/g of liver were observed on day 16.
The virus was detected in only 2 of 4 surviving animals on day 24 and was cleared by day
32. In the lung, a slight increase in day 8 virus titers was also noted in mice receiving
placebo relative to those treated with MY-24 (Figure 8C). Approximately 7 log10
CCID50/g of lung was detected on day 16, with a gradual decline in titers out to day 40.
Remarkably, >5 log10 CCID50/g of tissue virus burden was still present at the end of the
40-day experiment. The spleen was the only tissue in which the viral titers were higher
in the MY-24-treated animals on day 8 (Figure 8D). Remarkably, 3 of the 5 MY-24treated mice had >9.5 log10 CCID50/g. Spleen viral burden decreased on days 16-40, but
persisted similar to that observed in the lung. On day 8 of the infection, virus was found
only in brain tissue from a single placebo-treated animal (Figure 8E). However,
substantial titers were observed starting on day 16 ranging from 6 to 7.5 log10 CCID50/g
of brain. TCRV persistence was also observed in the kidneys of recovering MY-24treated mice (Figure 8F). As in most tissues, peak titers were
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Figure 8. Analysis of Serum and Tissue Virus Titers in AG129 Mice Infected with
TCRV and Treated with MY-24. Groups of 4-5 TCRV-infected animals treated with
MY-24 or placebo for up to 8 days starting on day 3 post-challenge, were sacrificed on
the specified days of infection for analysis of A) serum, B) liver, C) lung, D) spleen, E)
brain, and F) kidney virus titers. One mouse per MY-24 group at the 24, 32, and 40 h
time points succumbed prior to the time of sacrifice.
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observed on day 16 (~6.5 log10 CCID50/g of kidney), with a subsequent reduction in titers
as the experiment progressed. Notably, 60% (3 of 5) of mice that received placebo had
considerable day 8 viral titers, whereas none of the animals treated with MY-24 had
detectable virus until day 16. In general, MY-24-treated mice began to lose weight after
day 15 and started to recover the lost weight 6 days later (Figure 9). These data are
consistent with peak titers being observed primarily on day 16, with reductions in load in
most cases by day 24 (Figure 8).
In addition to assessing the viral titers out to 40 days post infection, we also
analyzed neutralizing anti-TCRV titers. The day-8 comparison data indicate that low
levels of neutralizing antibodies were elicited more quickly in placebo-treated animals
(Figure 10). By day 16, PRNT50 titers were at their peak in the MY-24-treated mice and
waned thereafter. Compared to the PRNT50 titers from immune serum from mice that
were boosted with live TCRV having survived infection with a non-lethal challenge dose,
the primary neutralizing antibody response was relatively weak.
To further gauge the effect of MY-24 treatment on the immune response during
TCRV infection in AG129 mice, a multiplex cytokine array analysis was conducted.
Cytokine levels were examined on day-8 serum and spleen samples from treated mice
and normal controls to assess the impact of MY-24 on systemic inflammation and locally
in the spleen. As shown previously in the natural history study (Figure 4), serum IFN-γ
was highly stimulated by TCRV infection (Figure 11, top panel). Most notably, however,
systemic IL-6 concentration was reduced significantly in MY-24-treated mice. The only
other significant difference was a
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Figure 9. Analysis of Weight Change in AG129 Mice Infected with TCRV and
Treated with MY-24 or Placebo. Mice from the longitudinal study described in Figure
8 were weighed every third day over the course of the experiment. Normal control mice
(n=5, with 1 mouse each sacrificed on days 8, 16, 24, 32, and 40) are included for
comparison. The data are represented as the group mean and standard deviation of the
percent change in weight of surviving animals relative to their starting weights.
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Figure 10. Neutralizing Antibody Levels During the Course of TCRV-Infection and
Recovery in AG129 Mice Treated with MY-24. Serum samples from TCRV-infected
animals treated with MY-24 or placebo, as indicated in the longitudinal study described
in Figure 8, were analyzed for neutralizing antibodies by PRNT. Normal serum from
uninfected mice and immune serum were included as controls. *P < 0.05.
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slightly reduced level of IL-1α observed in the placebo group relative to MY-24 and
normal control animals (Figure 11, upper panel). Although not statistically significant,
MY-24 also appeared to reduce the levels of TNF-α and MCP-1 (Figure 11, lower panel),
which in addition to IL-6, are linked to more severe forms of viral hemorrhagic fever
[101].
Consistent with the natural history data, IFN-γ, MIP-1α, and MCP-1 were clearly
induced in the spleens 8 days after TCRV infection (Figure 12). RANTES was the only
cytokine significantly altered by the MY-24 treatment (Figure 12, upper panel). Unlike
the trend of higher serum cytokine concentrations in the placebo-treated animals (Figure
11), greater levels of most cytokines and chemokines were observed in MY-24 treated
animals (Figure 12). This may be a reflection of the higher splenic virus titers in mice
treated with MY-24 (Figure 8D). It is conceivable that this more robust immune
response locally is preferable, in contrast to systemic inflammation that can trigger
vascular leakage.
Based on the natural history study, vascular permeability was examined on day 9 of
infection in selected tissues from treated mice to assess the impact of MY-24. Serum
EBD content was reduced in the TCRV-infected animals on day 9, suggesting vascular
hyperpermeability (Figure 13A). In liver, kidney, and spleen, higher average of tissue to
serum EBD ratio was observed in the TCRV-infected animals compared to the normal
sham-infected mice (Figure 13B, C, E). In general, the tissue EDB ratios were lower in
the MY-24 treated mice compared to placebo-treated animals, suggesting that MY-24
may be reducing vascular leakage.
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Figure 11. Comparative Analysis of Serum Cytokine Levels in Mice Infected with
TCRV and Treated with MY-24 or Placebo. As described in Figure 8, TCRV-infected
animals treated with MY-24 (n=5) or placebo (n=5) were sacrificed on day 8 relative to
the time of infection. Shown are the serum concentrations of selected cytokines
determined using a multiplexed array. *P < 0.05.
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Figure 12. Comparative Analysis of Spleen Cytokine Levels in Mice Infected with
TCRV and Treated with MY-24 or Placebo. As described in Figure 8, TCRV-infected
animals treated with MY-24 (n=5) or placebo (n=5) were sacrificed on day 8 relative to
the time of infection. Shown are the splenic concentrations of selected cytokines
determined using a multiplexed array. *P < 0.05.
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Figure 13. Evaluation of Vascular Permeability in TCRV-Infected Mice Treated
with MY-24. TCRV-infected mice treated with MY-24 or placebo, starting 3 days after
challenge, were infused with EB dye on day 9 of infection and systemic levels, as well as
leakage into the viscera was evaluated. A) Serum EB dye levels and ratios of tissue to
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*P < 0.05, ** P < 0.01 compared to sham-infected animals.
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However, the effect was slight in most cases, and the differences were not statistically
significant (Figure 13B-E).

41
CHAPTER 4
DISCUSSION
Junin and other South American hemorrhagic fever-causing arenaviruses pose a
considerable public health threat as emerging infectious disease agents and because of
their potential for intentional release. Further research to better understand the HF
disease process to aid the development of therapeutic and prophylactic interventions is
needed; however, all of the highly pathogenic NWA (Junin, Machupo, Guanarito, Sabia),
including the recently identified Chapare virus, require BSL-4 containment facilities for
their study. TCRV is a nonpathogenic NWA that is closely related to JUNV at the amino
acid level [7]. Due to the high cost and relative inaccessibility of BSL-4 facilities,
TCRV, which can be worked with in BSL-2 containment, facilitates early stage
preclinical development of promising antiviral compounds. However, despite its
relatedness to the highly pathogenic NWA, TCRV lacks the ability to antagonize the host
IFN response [88], and therefore requires AG129 IFN receptor-deficient mice as hosts for
productive infection. We employed the TCRV AG129 infection model to test the
hypothesis that MY-24 protects AG129 mice from lethal TCRV infection by subduing
the inflammatory response and limiting vascular leak.
The initial objective of this study was to characterize the natural history of disease
for the AG129 mouse TCRV infection model to compare the disease to the human
condition and determine the optimal time to evaluate the effects of MY-24 on the disease
process. The first part involved determining the kinetics of viral replication in blood and
tissues, assessing changes in clinical and hematologic parameters, tracking
histopathological changes, and cytokine profiling during the course of infection. The
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second part of the initial objective was to determine if and when TCRV infection
increased vascular permeability characteristic of viral HF syndromes. The careful
characterization of the model paved the way for studies to evaluate the effects of MY-24
on the host response to infection. The hypothesis suggesting that MY-24 is primarily
acting by dampening an overzealous inflammatory response was borne out of the findings
from the original work that reported robust protection afforded by MY-24 treatment
without any reduction in viral burden [76]. The results from the present study confirm
the previous finding; however, there was a trend suggesting that MY-24 may be having a
slight effect in reducing titers in serum and some tissues. Nevertheless, the lack of
statistically significant reductions in viral loads argues against a direct antiviral effect.
The current paradigm in the viral HF field is that exaggerated release of
proinflammatory cytokines into the circulation is the cause of the devastating vascular
leakage that leads to systemic shock, multi-organ failure, and death [101,109]. With this
in mind, the treatment of advanced cases of viral HF would likely require a combination
of an effective antiviral that directly disrupts the virus life cycle with an agent that can
limit the collateral damage caused by an overly aggressive host response. Our data
measuring vascular integrity in mice during the acute phase of TCRV infection indicates
that vascular leak is a part of the disease process, but its overall contribution to the
decline of the animals is difficult to measure.
In general, our collective natural history data are consistent with the idea that
increasing viral burden in the blood leads to release of proinflammatory cytokines that
drive vascular leak, which likely contributes to the demise of the animals. Indeed, lowlevel viremia begins on day 6 post infection (Figure 1), at which time elevations in
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systemic proinflammatory mediators such as IL-6, MCP-1, and TNF-α are detected
(Figure 4), and likely contribute to the increased vascular permeability which begins on
day 8 (Figure 7), and may contribute to mortality commonly observed between days 911. IL-6, which has been associated with severe disease in cases of viral HF and bacterial
sepsis [110,111], was slightly reduced on day 8 of infection in mice treated with MY-24.
This, in addition to slight reductions in the levels of MCP-1 and TNF-α, may be sufficient
to alter the disease course in a way that MY-24-treated animals are able to survive the
infection.
We predicted that a reduction in certain key inflammatory cytokines by MY-24
treatment would lead to diminished vascular leak. Although there was a trend of lower
accumulation of EBD in tissues of mice receiving MY-24, the differences were not
significant when measured on day 9 post infection (Figure 13). Because we only assayed
for vascular permeability on day 9, it is conceivable that MY-24 could have reduced the
duration of the vascular leak or delayed its onset. Such changes in the kinetics of
vascular leak could make a difference between life and death.
A modified version of our hypothesis is that MY-24 simply delays the deleterious
hyperimmune response, thereby changing the dynamics of the disease and the onset and
degree of vascular leak in a way that produces a more manageable disease. Our MY-24
cytokine profiling data are consistent with this idea (Figures 11, 12). Moreover,
neutralizing antibody responses appeared to be delayed in the MY-24 treated mice
compared to animals receiving placebo (Figure 10). Notably, surviving animals treated
with MY-24 appear ill (ruffled fur, lethargy, weight loss) during the second and third
weeks of the infection, compared to the mice treated with placebo which generally show
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clinical signs a day or two earlier. If too vigorous of a host response is largely
responsible for TCRV-induced disease, the ability of MY-24 to slow the process may be
sufficient to prevent mortality and allow the adaptive immune response to help control
the systemic infection, as suggested by the PRNT data and the eventual clearance of the
virus from the circulation.
As reported in our initial publication describing the TCRV model [76], the spleen
was the first site where significant viral loads were detected, and only it and liver tissue
presented with it considerable histopathology. Unexpectedly, we found >9.5 logs of
virus in the spleens of 3 of 5 mice treated with MY-24, approximately 3 logs greater than
the observed titers for the other two mice and the 5 animals that were treated with
placebo (Figure 9D). In fact, the spleen was the only tissue in which there was more
virus present compared to the placebo group, and this was also observed, but to a lesser
degree, in the previously reported study [76]. The effects of the increased viral load were
reflected in higher cytokine levels in day 8 spleen homogenates from MY-24-treated
mice. The importance of this finding and how it may contribute to the survival of mice
treated with MY-24 is unclear.
In regards to the immune response to TCRV in the AG129 mice, we were surprised
to see a general reduction in kidney and brain tissue cytokine levels (Figure 4). Although
virus did appear later in these tissues, we would not of predicted the overall suppressive
effect observed. The subdued proinflammatory cytokine response in kidney and brain
tissues presumably accounts for the lack of pathology. The more robust cytokine
responses in spleen, liver, and lung tissues were consistent with the more prominent
pathology observed in those tissues, and suggest immunopathology. Interestingly, the
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brain was the only tissue in which viral loads increased gradually out to 32 days post
infection (Figure 8E). This is striking in that systemic virus was cleared by day 24
(Figure 8A). This suggests that the high and constant titers found in the brains of TCRVchallenged animals on days 24, 32, and 40 were the results of viral replication and
persistence in the brain, and not continued seeding from circulating virus.
Arenaviruses are zoonotic agents that produce subclinical infections in their
respective rodent reservoir species. An interesting and unexpected finding from our
studies was that surviving mice go on to develop chronic infection in various tissues,
despite clearing the virus systemically. We found that the weight loss nadir in MY-24treated mice from days 18 to 21, prior to the recovery of the animals, is consistent with
the systemic clearance of the virus between the 16 and 24 day time points. Importantly,
however, the AG129 mice lack type I and II IFN receptors, and thus it is difficult to make
conclusions regarding the biological significance of this finding. Notwithstanding, it is
likely that arenaviruses antagonize native rodent IFN response pathways as a mechanism
by which they establish chronic carrier states. Additional studies investigating the longterm carriage of TCRV in AG129 mice may lead to new insights in arenavirus-rodent
reservoir interactions.
Taken together, our data provides evidence that an increase in systemic TCRV
levels is followed by hypercytokinemia, which likely drives the observed vascular leak in
the AG129 mouse model. Ensuing plasma volume loss, organ failure, and shock are
believed to be the cause of death. In MY-24-treated mice there was an overall slight
reduction in serum viral load, a slight decrease in IL-6, IFN-γ and MCP-1 (with a
minimal reduction in other proinflammatory cytokines) (Figure 11), and a trend of
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reduced vascular permeability in several tissues (Figure 13). We expected a more
dramatic effect for MY-24 treatment in reducing inflammatory responses and improving
vascular integrity, which was the basis of our hypothesis. However, it is possible that
even a slight effect in the measured parameters could be sufficient to alter the outcome of
TCRV infection. Certainly, there are other factors that contribute to the fatal outcome of
TCRV infection in AG129 mice, and MY-24 may be having a more substantial effect in
that context. What appears to be clear is that despite having activity against TCRV in
vitro, there is little evidence for a direct antiviral effect targeting the virus life cycle in
vivo. Our continued line of thinking is that MY-24 is blunting several response

pathways in the AG129 host response sufficient to alter the outcome of TCRV
infection.
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Table A1. Summary of Histopathology Findings from Mice Infected with TCRV

Mouse no.

Liver

Spleen

Lung

Kidney

Brain

Day Post Infection

211

Hyperplastic splenic
follicles with
increased numbers
of neutrophils

7

212

Hyperplastic splenic
follicles

7

228

Hyperplastic splenic
follicles with
increased numbers
of neutrophils

7

229

Hyperplastic splenic
follicles

7

213

Moderate numbers
of lymphocytes and
histiocytes infiltrate
portal zones Widely
scattered individual Hyperplastic splenic
hepatocytes are
follicles with
degenerate/necrotic scattered lytic cells
and are surrounded
by small numbers of
neutrophils
or lymphocytes.

214

"Moderate numbers
of lymphocytes and
histiocytes infiltrate
Hyperplastic splenic
portal zones Widely
follicles with
scattered individual
scattered lytic
hepatocytes are
cells and increased
degenerate/necrotic
numbers of
and are surrounded
neutrophils.
by small numbers of
neutrophils
or lymphocytes."

8

230

Moderate numbers
of lymphocytes and
histiocytes infiltrate
portal
zones (liver). Widely Hyperplastic splenic
scattered individual
follicles with
hepatocytes are
scattered lytic cells
necrotic and
are surrounded by
small numbers of
neutrophils or
lymphocytes.

8

Mild perivascular
edema with small
numbers of mixed
inflammatory cells
or moderate
perivascular
hemorrhage
surrounding
scattered
pulmonary
arterioles.

8

59

Mouse no.

246

Liver

Spleen

Lung

Moderate numbers
of lymphocytes and
histiocytes infiltrate
portal
zones (liver).
Hyperplastic splenic
Scattered individual
follicles with
hepatocytes are
increased numbers
degenerate/necrotic
of neutrophils.
and are surrounded
by small numbers of
neutrophils or
lymphocytes.

Kidney

Brain

Day Post Infection

8

215

Moderate
numbers of
lymphocytes,
neutrophils and
histiocytes infiltrate
Perivascular edema
portal
fluid with small
zones and
Hyperplastic splenic
numbers of
accumulate in
neutrophils
follicles with
sinusoidal spaces. scattered lytic cells.
or perivascular
Scattered individual
hemorrhage
hepatocytes are
surrounds scattered
arterioles.
degenerate/necrotic
and are surrounded
by aggregates of
neutrophils and
lymphocytes.

9

216

Moderate numbers
of lymphocytes,
neutrophils and
histiocytes
infiltrate portal
zones and
accumulate in
sinusoidal spaces. Hyperplastic splenic
Scattered individual
follicles.
hepatocytes are
degenerate/necrotic
and are
surrounded by
aggregates of
neutrophils and
lymphocytes.

Esophagus:
aggregates of
neutrophils
multifocally widen
the

9

247

Moderate numbers
of lymphocytes,
neutrophils and
histiocytes infiltrate
portal zones (liver)
and accumulate in
sinusoidal spaces.
Scattered
Hyperplastic splenic
individual
follicles
hepatocytes are
degenerate/necrotic
and are surrounded
by
aggregates of
neutrophils and
lymphocytes.

Small numbers of
neutrophils are
within scattered
alveoli

9

60

Mouse no.

248

217

218

Liver

Moderate numbers
of lymphocytes,
neutrophils and
histiocytes infiltrate
portal zones (liver).
Widely scattered
individual
hepatocytes are
degenerate/necrotic
and are surrounded
by
small numbers of
neutrophils or
lymphocytes.

Spleen

Lung

Lymphocytic/neutro
philic
myocarditis(section
of heart
accompanying
lung). Heavy
infiltrate of
Hyperplastic splenic
lymphocytes and
follicles with
histiocytes with
increased numbers
fewer
of neutrophils.
neutrophils in fat
around heart and
adjacent segments
of pleurae. A
large aggregate of
pyogranulomatous
inflammation
replaces a group of
alveoli (lung)

Moderate numbers
of
lymphocytes,
neutrophils and
histiocytes infiltrate
portal zones (liver)
and accumulate in Hyperplastic splenic
sinusoidal spaces.
follicles with
Scattered individual scattered lytic cells
hepatocytes
and interstitial
are
fibrin.
degenerate/necrotic
and are surrounded
by aggregates of
neutrophils
and lymphocytes.

Kidney

Brain

Day Post Infection

9

Esophagus:
aggregates of
neutrophils
multifocally widen
the
submucosa.
Neutrophils and
histiocytes infiltrate
periesophageal
connective tissue
unilaterally.

10

Moderate numbers
of lymphocytes,
neutrophils and
histiocytes
Scattered
infiltrate portal
perivascular and
peribronchiolar
zones (liver) and
accumulate in
Hyperplastic splenic hemorrhages. Some
follicles with
larger
sinusoidal spaces.
vessels are also
Scattered individual regularly scattered
hepatocytes are
lytic cells.
surrounded by
degenerate/necrotic
moderate numbers
and are
of lymphocytes and
surrounded by
neutrophils.
aggregates of
neutrophils and
lymphocytes.

10

61

Mouse no.

249

250

300

Liver

Spleen

Moderate numbers
of lymphocytes,
neutrophils and
histiocytes
infiltrate portal
zones (liver) and
accumulate in
Hyperplastic splenic
sinusoidal spaces.
follicles with
Scattered individual regularly scattered
lytic cells.
hepatocytes are
degenerate/necrotic
and are
surrounded by
aggregates of
neutrophils and
lymphocytes.

Lung

Scattered
perivascular and
peribronchiolar
hemorrhages.

Moderate numbers
of lymphocytes,
neutrophils and
histiocytes infiltrate
portal zones (liver)
and
accumulate in
Hyperplastic splenic
Mild
sinusoidal spaces.
follicles with
neutrophilic/lympho
Scattered individual
scattered lytic cells
cytic pleuritis.
hepatocytes are
degenerate/necrotic
and are surrounded
by aggregates of
neutrophils and
lymphocytes.

Moderate numbers
of lymphocytes,
neutrophils and
histiocytes
infiltrate portal
zones (liver) and
Hyperplastic splenic
follicles with
small clusters
accumulate in
scattered lytic cells
sinusoidal spaces.
and interstitial
Scattered individual
fibrin.
hepatocytes are
degenerate/necrotic
and are surrounded
by aggregates of
neutrophils and
lymphocytes.

Kidney

Brain

Day Post Infection

10

10

10

62

Mouse no.

Liver

Spleen

Lung

Kidney

Brain

Day Post Infection

237 Sham

7

238 Sham

8

239 Sham

9

240 Sham

Scattered
perivascular and
peribronchiolar
hemorrhages

10

